Zuropraz-D 20 Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release formulation of Zuropraz-D 20 ensures prolonged therapeutic plasma concentrations, enhancing patient compliance through once-daily dosing. This combination is particularly beneficial in patients requiring both acid suppression and prokinetic action to manage complex upper gastrointestinal symptoms. Zuropraz-D 20 should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, and in those with underlying cardiac conditions due to Domperidone’s potential to prolong QT interval. Regular monitoring is recommended during prolonged therapy. This medication is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or prolactinoma.